Hemp  is grown commercially for its leaves, stalks and flowers which contain cannabidiol (CBD)[1] and many other cannabinoids[2]. (




Welcome to Hempceuticals

Naturally Curious

A hempceutical[1] is a pharmaceutical alternative which contains hemp derived CBD and/or CBG[2], CBN[3], CBC[4] and/or related cannabinoid compounds for the purpose of the physiological benefits.  In the US, "hempceuticals” and all other products containing hemp derived Cannabinoids are regulated by the FDA and are not currently permissibly labelled as dietary supplements.  Product form factors vary and include ingestible options such as oil drops, gummies, capsules, soft-gels, candies, chocolates as well as topicals such as creams, lotions, salves, skin care products and topical patches, all of which are widely available for humans, dogs, cats and horses.  Hempceuticals always contain hemp derived CBD or other plant derived cannabinoids and may or may not contain hemp seed[5] oil from the hemp plant.  Hemp seed oil is easier and less expensive to produce, and does not contain CBD.

                 o   1.1 United States


[1] xxx






A Hempceutical and/or Hempceuticals containing hemp derived CBD or other plant derived cannabinoids are treated differently in different jurisdictions around the world. [12]

United States[edit]

According to the US regulatory body, the Federal Drug Administration,” Cannabis is a plant of the Cannabaceae family and contains more than eighty biologically active chemical compounds. The most commonly known compounds are phytocannabinoid  tetrahydrocannabinol (THC) delta-9[1] and cannabidiol (CBD). Parts of the Cannabis sativa plant have been controlled under the Controlled Substances Act (CSA) since 1970 under the drug class "Marihuana" (commonly referred to as "marijuana") [21 U.S.C. 802(16)]. "Marihuana" is listed in Schedule I of the CSA due to its high potential for abuse, which is attributable in large part to the psychoactive effects of THC, and the absence of a currently accepted medical use of the plant in the United States.” [1]

The 2018 Farm Bill[2]; How hemp is now defined and the impact for Hempceuticals and hemp derived products with regard to FDA-regulated products

According to the FDA “At the federal level, the Agriculture Improvement Act of 2018, Pub. L. 115-334, (the 2018 Farm Bill) was signed into law on Dec. 20, 2018. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." These changes include removing hemp from the CSA, which means that cannabis plants and derivatives that contain no more than 0.3 percent THC on a dry weight basis are no longer controlled substances under federal law.

The 2018 Farm Bill, however, explicitly preserved the FDA’s authority to regulate products containing cannabis or cannabis-derived compounds under the FD&C Act and section 351 of the Public Health Service Act (PHS Act). FDA treats products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products — meaning they’re subject to the same authorities and requirements as FDA-regulated products containing any other substance. This is true regardless of whether the cannabis or cannabis-derived compounds are classified as hemp under the 2018 Farm Bill. [1]


[1] tetrahydrocannabinol 



A market research report produced in 2019 by Brightfield Group, a market intelligence firm for the legal CBD and cannabis industries, uncovered numerous shifts across the U.S. CBD industry, signaling a seven-fold increase in the market.  With hemp-derived CBD and hempceutical products gaining in popularity, in line with health, wellness, and anti-pharma trends, and product availability and variety increasing, the market was on track to grow to $23.7 billion through 2023. [2]    With Covid-19 affecting most consumer markets, in July of 2020, Brightfield Group revised their estimates and believe sales will reach $12.4 billion by 2023 and $16.8 billion by 2025.

Those figures are more in line with projections made by BDSA, a Colorado based research firm that analyzes cannabis trends and offers forecasts for the market. Last  September the BDSA quoted 2020 CBD sales would reach $6.5 billion in 2020.  By 2023, BDSA believes U.S. spending on CBD products will approach $16 billion. [3]


Classification of Hempceuticals:

Hempceuticals are products containing hemp derived CBD and/or other Cannabinoids that are purported to provide health or wellness benefits, in addition to the basic nutritional or functional value of the product the CBD or cannabinoid has been mixed with.  A hempceutical can be a gummy containing Cannabidiol (CBD) in addition to several other ingredients, as well as a tincture made with a carrier oil such as MCT, hemp oil, or any other carrier such as a topical cream infused with Cannabidiol (CBD), or massage oils, to help treat sore joints and manage pain.  Depending on the jurisdiction, products may claim to manage pain, improve mood, reduce inflammation, promote sleep, or support balance structure or function of the body- known as homeostasis.[8]


The word "hempceutical" is a portmanteau of the words "hemp" and "pharmaceutical",[4].  As a relatively new word, “hempceutical” has yet to be recognized and included in dictionaries, such as The Oxford English Dictionary, [5] The Merriam Webster Dictionary[6] or [7]


Because hempceuticals are largely unregulated, these consumer products are the subject of marketing hype rather than actual clinical testing, and for many, it is not yet known whether they provide more benefit than risk for consumers. [9]  For many of these products, the most compelling evidence for efficacy remains anecdotal or, at best, based on hints of benefit from small or poorly controlled studies.  When product claims are not aligned with the analysis or evidence, there can be legal consequences:  After reviewing claims made by companies marketing CBD and hempceutical products, and after conducting independent third party tests to determine the potencies of CBD contained in branded products, the FDA found discrepancies and issued warning letters to a number of manufacturers[10]


  1. ^ FDA Website Retrieved 2020-11-03

  2. ^ Brightfield Group Retrieved 2020-11-05

  3. ^ THC.Net Retrieved 2020-11-05

  4. ^ Integrity Hempceuticals Retrieved 2020-11-05

  5. ^ The Oxford English Dictionary Retrieved 2020-11-05

  6. ^ Merriam Webster Dictionary Retrieved 2020-11-05

  7. ^ Retrieved 2020-11-05

  8. ^ Homeostasis Retrieved 2020-11-05

  9. ^ Everything you need to know about CBD Oil. 2020-11-05

  10. ^ FDA issued warning letters to CBD companies Retrieved 2020-11-05

  11. ^ Hempseed vs. CBD – The differences explained Retrieved 2020-11-05

  12. ^ CBD laws around the world


Posts are coming soon
Stay tuned...